Beijing Centergate Technologies (Holding) Co., Ltd. has announced that its subsidiary, Beijing Huasu Pharmaceutical Co., Ltd., recently obtained a "Drug Clinical Trial Approval Notice" from China's National Medical Products Administration for methylphenidate hydrochloride prolonged-release chewable tablets (40mg dosage).
The medication has been cleared for clinical trials targeting attention deficit hyperactivity disorder (ADHD).
According to current statistics, only one original imported drug has received market approval in China for this indication. This approval positions Beijing Huasu as the first domestic pharmaceutical company to obtain clinical trial permission for a generic version of this treatment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.